Prevention and treatment of ocular side effects with a...

Details Prevention and treatment of ocular side effects with a... Prevention and treatment of ocular side effects with a...

2006-10-11

2010-06-29

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

Reexamination Certificate

active

07745400

ABSTRACT:
Presently described are methods of administration and associated treatment of one or more ocular conditions using cyclosporine, or an analog or derivative thereof. The ocular conditions can be a result of treatment using other therapeutic agents, such as chemotherapy agents, antiviral agents and immunomodulators.

REFERENCES:
patent: 4388229 (1983-06-01), Fu
patent: 4388307 (1983-06-01), Cavanak
patent: 4649047 (1987-03-01), Kaswan
patent: 4814323 (1989-03-01), Andrieu et al.
patent: 4839342 (1989-06-01), Kaswan
patent: 4996193 (1991-02-01), Hewitt et al.
patent: 5047396 (1991-09-01), Orban et al.
patent: 5051402 (1991-09-01), Kurihara et al.
patent: 5294604 (1994-03-01), Nussenblatt
patent: 5296158 (1994-03-01), MacGilp et al.
patent: 5342625 (1994-08-01), Hauer et al.
patent: 5411952 (1995-05-01), Kaswan
patent: 5474979 (1995-12-01), Ding et al.
patent: 5543393 (1996-08-01), Kim et al.
patent: 5589455 (1996-12-01), Woo
patent: 5614491 (1997-03-01), Walch et al.
patent: 5639724 (1997-06-01), Cavanak
patent: 5652212 (1997-07-01), Cavanak et al.
patent: 5753166 (1998-05-01), Dalton et al.
patent: 5759997 (1998-06-01), Cavanak
patent: 5766629 (1998-06-01), Cho et al.
patent: 5798333 (1998-08-01), Sherman
patent: 5827822 (1998-10-01), Floc'h et al.
patent: 5827835 (1998-10-01), Kabra
patent: 5834017 (1998-11-01), Cho et al.
patent: 5891846 (1999-04-01), Ishida et al.
patent: 5916589 (1999-06-01), Hauer et al.
patent: 5951971 (1999-09-01), Kawashima et al.
patent: 5962014 (1999-10-01), Hauer et al.
patent: 5962017 (1999-10-01), Hauer et al.
patent: 5962019 (1999-10-01), Cho et al.
patent: 5977066 (1999-11-01), Cavanak
patent: 5977067 (1999-11-01), Evers et al.
patent: 6007840 (1999-12-01), Hauer et al.
patent: 6024978 (2000-02-01), Hauer et al.
patent: 6057289 (2000-05-01), Mulye
patent: 6190691 (2001-02-01), Mak
patent: 6197335 (2001-03-01), Sherman
patent: 6245805 (2001-06-01), Broder et al.
patent: 6254860 (2001-07-01), Garst
patent: 6254885 (2001-07-01), Cho et al.
patent: 6267985 (2001-07-01), Chen et al.
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6294192 (2001-09-01), Patel et al.
patent: 6306825 (2001-10-01), Cavanak
patent: 6350442 (2002-02-01), Garst
patent: 6420355 (2002-07-01), Richter et al.
patent: 6468968 (2002-10-01), Cavanak et al.
patent: 6475519 (2002-11-01), Meinzer et al.
patent: 6486124 (2002-11-01), Olbrich et al.
patent: 6569463 (2003-05-01), Patel et al.
patent: 6582718 (2003-06-01), Kawashima et al.
patent: 6638522 (2003-10-01), Mulye
patent: 6656504 (2003-12-01), Bosch et al.
patent: 6720001 (2004-04-01), Chen et al.
patent: 6723339 (2004-04-01), Meinzer et al.
patent: 6852718 (2005-02-01), Burkamp et al.
patent: 6916785 (2005-07-01), Patel
patent: 2001/0003589 (2001-06-01), Neuer et al.
patent: 2001/0036449 (2001-11-01), Garst
patent: 2001/0041671 (2001-11-01), Napoli
patent: 2002/0012680 (2002-01-01), Patel et al.
patent: 2002/0013272 (2002-01-01), Cavanak et al.
patent: 2002/0016290 (2002-02-01), Floc'h et al.
patent: 2002/0016292 (2002-02-01), Richter et al.
patent: 2002/0025927 (2002-02-01), Olbrich et al.
patent: 2002/0045601 (2002-04-01), Kawashima et al.
patent: 2002/0107183 (2002-08-01), Petswzulat et al.
patent: 2002/0119190 (2002-08-01), Meinzer et al.
patent: 2002/0165134 (2002-11-01), Richter et al.
patent: 2003/0060402 (2003-03-01), Cavanak et al.
patent: 2003/0108626 (2003-06-01), Benita et al.
patent: 2003/0133984 (2003-07-01), Ambuhl et al.
patent: 2003/0143250 (2003-07-01), Hauer et al.
patent: 2003/0147954 (2003-08-01), Yang et al.
patent: 2003/0166517 (2003-09-01), Fricker et al.
patent: 2003/0211983 (2003-11-01), Petszulat et al.
patent: 2003/0212090 (2003-11-01), Chen et al.
patent: 2003/0215496 (2003-11-01), Patel et al.
patent: 2004/0048789 (2004-03-01), Patel
patent: 2004/0092435 (2004-05-01), Peyman
patent: 2004/0101552 (2004-05-01), Patel
patent: 2004/0102366 (2004-05-01), Patel
patent: 2004/0106546 (2004-06-01), Napoli
patent: 2004/0161458 (2004-08-01), Meinzer et al.
patent: 2004/0167063 (2004-08-01), Cavanak et al.
patent: 2004/0185068 (2004-09-01), Yu et al.
patent: 2004/0198645 (2004-10-01), Ambuhl et al.
patent: 2005/0013854 (2005-01-01), Mannino et al.
patent: 2005/0025810 (2005-02-01), Peyman
patent: 2005/0048087 (2005-03-01), Posanski
patent: 2005/0059583 (2005-03-01), Acheampong et al.
patent: 2005/0118254 (2005-06-01), Choi et al.
patent: 2005/0129718 (2005-06-01), Sherman
patent: 2005/0147659 (2005-07-01), Carli et al.
patent: 2005/0196370 (2005-09-01), Yu et al.
patent: 0146341 (1984-12-01), None
patent: 0471293 (1992-02-01), None
patent: 0547229 (1992-06-01), None
patent: 956853 (1999-05-01), None
patent: WO00/00179 (2000-01-01), None
patent: WO/08085 (2000-02-01), None
patent: WO01/32142 (2001-05-01), None
“Questions and Answers About Taxotere® Injection Concentrate”, Patient Information Leaflet by Aventis Pharmaceuticals Inc., Rev. May 2004.
Schmid et al. Update on Ocular Complications of Systemic Cancer Chemotherapy. Survey Of Ophthalmology. Jan.-Feb. 2006, vol. 51, No. 1, pp. 19-40.
Kuwano et al, “Cyclosporine A Formulation Affects Its Ocular Distribution in Rabbits”, Pharmaceutical Research, vol. 19, No. 1, Jan. 2002, 108-111.
Castillo, et al., “Influence of topical Cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein,” Documenta Ophthalmologica, 1995, 91, 49-55.
Restasis® Package Insert, (cyclosporine ophthalmic emulsion)0.05%, Sterile, Preserviatve-Free, 2 page, (2004).
Uniqema, Tween™ Series. Polyoxyethylene derivatives of sorbitan esters. 2 pages, (2004).
Rita, Ritabate 40, INCI Nomenclature (formerly CTFA) . . . Polysorbate 40, 1 page, (1994).
Rita, Ritabate 60, INCI Nomenclature (formerly CTFA) . . . Polysorbate 60, 1 page.
Rita, Ritabate 20, INCI Nomenclature (formerly CTFA) . . . Polysorbate 20, 1 page, (1994).
TheMerkIndex Results-Form View, Monography No. 07664, Titles: Polysorbates, 1 page, and Polyoxyethylene, 1 page, (2006).
Sandimmue® Package Insert, (cyclosporine oral solution), RxList, The Internet Drug Index, 3 pp, (2006).
Benitez, et al., “Influence of topical Cyclosporine A and dissolvent on corenal epithelium permeability of fluororescein,” Ophthalmologica 91: 49-55, 1995.
http://thornleycompany.com/Products/PEGsters.htm, (2006).
www.lipochemicals.com document on Emulsifiers and Emulsifying systems (Aug. 20, 2002), pp. 1-5.
Lanzetta et al, “Major ocular complications after organ transplantation”, Transplantation Proceedings, vol. 36, No. 10, Dec. 1, 2004.

Affiliated with

Also associated with

Rating

Prevention and treatment of ocular side effects with a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Prevention and treatment of ocular side effects with a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of ocular side effects with a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4202309